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ABSTRACT
The aim of the study was to investigate the association between psychological characteristics
and biological markers of adherence in chronic kidney disease patients receiving conservative
therapy, hemodialysis, peritoneal dialysis (PD), or kidney transplantation.
Seventy-nine adult patients were asked to complete the following questionnaires: Toronto
Alexithymia scale, Snaith–Hamilton Pleasure Scale, and Short Form Health Survey. Biological
markers of adherence to treatment were measured.
Peritoneal dialysis patients showed a lower capacity to feel pleasure from sensorial experience
(p¼ .011) and a higher values of phosphorus compared to the other patients’ groups (p¼ .0001).
The inability to communicate emotions was negatively correlated with hemoglobin levels
(r¼(0).69; p¼ .001) and positively correlated with phosphorus values in the PD patients (r¼ .45;
p¼ .050).
Findings showed higher psychological impairments and a lower adherence to the treatment in
PD patients and suggest the implication of emotional competence in adherence to treatment.
ARTICLE HISTORY
Received 26 July 2016
Revised 10 September 2016
Accepted 27 October 2016
KEYWORDS
Hemodialysis; alexithymia;
kidney disease; renal failure;
quality of life
Background
The prevalence of chronic kidney disease (CKD) is 11%
of the adult population in the United States (19.2 mil-
lion): 5.9 million have stage 1 of CKD (persistent albu-
minuria with normal glomerular filtration rate), whereas
the remaining 13 million have variable degrees of kid-
ney dysfunction, from mild to severe functional
impairment.1
Previous studies showed that end stage renal disease
(ESRD) patients undergoing peritoneal dialysis (PD) or
hemodialysis (HD) presented lower adherence, higher
psychological distress, and lower quality of life com-
pared to healthy subjects.2,3 Moreover, lack of adher-
ence and higher psychological distress seem to
contribute to a greater morbidity and earlier mortality
in CKD patients.2
Others studies reported that HD patients showed
lower levels of quality of life compared to patients on
PD treatment,4 and that kidney transplantation (KT)
patients showed higher quality of life compared to
patients undergoing other different therapies.5–7
Many studies investigated on the health and quality
of life in ESRD.8–10 The comparisons between HD and
PD on the health related quality of life produced con-
flicting results.8 Many studies suggested that PD
patients perceived lower distress and higher psycho-
logical well-being compared to patients undergoing
other replacement therapies.9,10 The fact that PD treat-
ment allows patients to receive the treatment at home
avoiding in-hospital care could be the reason for the
lower distress in these patients.
Some studies showed that impairments in emotional
ability, that seems to be a risk factor for mortality,11
could occur as a reaction to the ESRD in HD patients.10
Moreover, many studies demonstrated that psycho-
logical disease can affect adherence to medical
treatment12 and a recent review showed that non-
adherence is a persistent concern in PD patients. In the
therapy planning of ESRD patients, it seems very
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important to take into consideration adherence behav-
ior of patients in order to improve outcomes.13
On the bases of these findings, it seems mandatory
to explore which psychological characteristics are asso-
ciated with adherence behaviors.
The aim of the present study was to investigate the
association between psychological impairments and
biological markers of adherence in CKD patients man-
aged with different kinds of treatment (PD, HD, KT, and
conservative treatment, CT).
The hypothesis was that PD and HD patients will
show higher psychological impairment and lower adher-
ence to treatment compared to CT and KT patients.
Methods
Participants
Following local Ethical Committee approval, 79 adult
patients with CKD were recruited in three different cen-
ters of dialysis in Italy from March 2013 to October
2013. Inclusion criteria were: age between 39 and 80
years, level of education no lower than primary school,
Italian or foreign citizenship with knowledge of
Italian language, and absence of psychopathological
diagnoses.
The sample was differentiated in patients treated
with PD (n¼ 39), with hemodialysis (n¼ 35), with
conservative therapy (n¼ 16) and nine transplanted
patients (KT).
Procedure
During a follow-up nephrological visit, a psychologist,
after delivery of informed consent, asked to patients to
complete three questionnaires: Short Form Health
Survey (SF-36), Snaith–Hamilton Pleasure Scale (SHAPS),
and Toronto Alexithymia Scale (TAS-20).
Measures
The SF-36 contains 36 questions that assess eight
aspects of Quality of Life: physical functioning (PF), role-
physical functioning (RP), bodily pain (BP), general
health (GH), vitality (VT), social functioning (SF), role-
emotional functioning (RE), and mental health (MH). For
each question, a score from 0 to 100 is given. Higher
scores reflect better functioning. Internal consistency,
test–retest reliability and validity of the content range
from 0.68 to 0.93, 0.60 to 0.81, and 0.42 to 0.84,
respectively.14
The SHAPS is a brief 14-item self-report questionnaire
that intends to measure hedonic tone and its absence,
anhedonia. These 14 items cover four domains of
hedonic experience: interest/pastimes, social inter-
action, sensory experience, and food/drink. The SHAPS
showed adequate psychometric properties in clinical
and healthy samples. The internal consistency was 0.91.
A one-factor solution emerged for the SHAPS (Eigen-
values of the first two initial factors were 5.95 and 0.43,
respectively). The SHAPS is a reliable, valid, and unidi-
mensional instrument used to assess the hedonic cap-
acity in adult samples.15
The TAS-20 is a self-report scale comprised of 20
items.14 Each item is rated on a five-point Likert scale
ranging from 1 (strongly disagree) to 5 (strongly
agree). The first factor (F1) in the three-factor model
for the TAS-20 consists of seven items assessing the
ability to identify feelings and emotions and to distin-
guish them from the somatic sensations that accom-
pany emotional arousal. Factor 2 (F2) consists of five
items assessing the ability to describe feelings and
emotions to other people. Factor 3 (F3) consists of
eight items assessing externally oriented thinking. The
internal reliabilities of the total, F1, F2, and F3 scores
meet the recommended standard value (Cronbach’s
alpha>.70).16
Biological measurements
Blood was drawn in the morning after an overnight
fast of at least 12 h, before dialysis in PD and HD
patients. In all the patients, the levels of fasting
plasma glucose (mg/dL), hemoglobin (g/dL), serum
total cholesterol (mg/dL), triglycerides (mg/dL), high-
density lipoprotein (HDL) (mg/dL), low-density lipopro-
tein (LDL) (mg/dL), azotemia (mg/dL), calcium (mg/
dL), phosphorus (mg/dL), CaP (mg/dL), natrium
(mEq/L), potassium (mEq/L), C reactive protein
(mg/dL), were measured using standard automated
techniques. The estimation glomerular filtration rate
(eGFR) was calculated with the abbreviated modifica-
tion of diet in renal disease formula, as defined by
Levey et al.17
Statistical analyses
Results are reported as mean values ± standard devia-
tions (SD) for dependent variables.
ANOVAs (Fisher F) were performed in order to test
differences among the four groups of patients (PD, HD,
CT, KT) on the dependent variables. A p value of p< .05
was considered significant. Statistical analyses were per-
formed using Statistica Version 5.1 software (StatSoft,
Tulsa, OK).
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Results
General information of CKT patients has been reported
in Table 1. KT patients (47.9 ± 11.4; F/M: 1/8) were sig-
nificantly younger (F(3,75)¼ 9.6; p¼ .00001) than PD
(64.6 ± 10.6; p¼ .0001; F/M: 4/15), HD (63.3 ± 11.0;
p¼ .0001; F/M: 16/19), and CT (71.0 ± 7.9; p¼ .0001; F/M:
3/13) patients.
In Table 2, SF-36 variables did not show any signifi-
cant difference among the groups.
As regard to SHAPS variables, only the sensorial
experiences dimension showed an effect among groups
(F(3,75)¼ 4.4; p¼ .006) whereas PD patients (3.52 ± 0.84)
presented significantly lower scores than HD (3.9 ± 0.3;
p¼ .003), CT (4.0 ± 0.0; p¼ .002), and KT patients
(4.0 ± 0.0; p¼ .011).
Moreover, TAS-20 F3 dimension showed a significant
effect among the four groups (F(3,75)¼ 3.9; p¼ .012)
where HD patients (18.4 ± 5.1) showed significantly
lower values than CT patients (23.2 ± 4.7; p¼ .001).
As shown in Table 3, blood urea nitrogen
(F(3,75)¼ 14.2; p¼ .001), potassium (F(3,75)¼ 4,3;
p¼ .007), calcium (F(3,75)¼ 3.9; p¼ .001), phosphorus
concentration (F(3,75)¼ 19.0; p< .0001), hemoglobin
level (F(3,75)¼ 8.2; p¼ .0001) showed a significant
effect among groups.
Post hoc comparisons showed that: PD patients
(122.8 ± 47.9) had significantly higher blood urea nitro-
gen values than CT patients (81.1 ± 40.3; p¼ .001);
moreover, HD patients (141.6 ± 32.0) presented signifi-
cantly higher blood urea nitrogen values than KT
patients (69.8 ± 34.5; p¼ .0001); PD patients (4.5 ± 0.6)
presented significantly lower potassium values than HD
(5.1 ± 0.7; p¼ .28) and KT patients (5.1 ± 0.4; p¼ .009);
HD patients (8.5 ± 1.4) presented significantly lower
Table 2. ANOVAs and post hoc comparisons among the different chronic kidney disease treatments (Peritoneal dialysis,
Hemodialysis, Conservative treatment, and Kidney transplant) on Short Form Health Survey, Snaith–Hamilton Pleasure Scale, and
Toronto Alexithymia Scale dimensions.
Peritoneal dialysis
(n¼ 19)
(PD)
Hemodialysis
(n¼ 35)
(HD)
Conservative treat-
ment
(n¼ 16)
(CT)
Kidney transplant
(n¼ 9)
(KT) F(3,75) p Post hoc
Short form health survey
Physical functioning 55.5 ± 34.2 46.9 ± 29.0 54.4 ± 30.5 68.9 ± 32.6 0.9 .450 –
Role-physical
functioning
39.5 ± 44.3 32.6 ± 40.0 37.5 ± 40.8 27.8 ± 42.3 0.2 .881 –
Bodily pain 54.9 ± 27.7 42.3 ± 24.5 48.4 ± 26.3 61.1 ± 41.6 2.1 .110 –
General health 38.5 ± 21.4 33.8 ± 23.1 46.0 ± 19.1 41.1 ± 27.1 1.1 .337 –
Vitality 50.3 ± 23.2 43.5 ± 23.5 46.2 ± 22.2 59.4 ± 25.3 1.2 .360 –
Social functioning 61.8 ± 31.3 55.5 ± 32.7 54.7 ± 23.2 80.5 ± 23.5 1.9 .138 –
Role-emotional
functioning
43.7 ± 44.5 40.8 ± 43.3 45.8 ± 41.9 66.7 ± 40.8 0.9 .458 –
Mental health 61.9 ± 24.8 57.9 ± 29.2 51.2 ± 22.5 67.5 ± 17.7 0.9 .446 –
Snaith-hamilton pleasure scale
Total score 12.4 ± 2.6 13.0 ± 1.2 13.4 ± 0.7 14.0 ± 0.0 2.5 .067 KT> PD (p¼ .014)
Interest/pastimes 3.5 ± 1.1 3.4 ± 0.9 3.6 ± 0.6 4.0 ± 0.0 1.4 .233 –
Food/drink 1.7 ± 0.7 1.8 ± 0.3 2.0 ± 0.0 2.0 ± 0.0 2.2 .098 CT> PD (p¼ .024)
Social interaction 3.7 ± 0.4 3.8 ± 0.3 3.8 ± 0.4 4.0 ± 0.0 1.1 .359 –
Sensory experience 3.5 ± 0.8 3.9 ± 0.3 4.0 ± 0.0 4.0 ± 0.0 4.3 .006 KT> PD (p¼ .011)
HD> PD (p¼ .003)
CT> PD (p¼ .002)
Toronto alexithymia scale
Total score 48.8 ± 12.9 45.4 ± 14.1 53.6 ± 9.8 42.9 ± 10.0 2.0 .117 –
F1 ability to identify
feelings
14.7 ± 7.9 15.4 ± 6.8 17.6 ± 5.5 11.5 ± 3.7 1.6 .183 –
F2 ability to describe
feelings
13.7 ± 5.1 11.6 ± 5.3 12.9 ± 2.3 10.0 ± 3.5 1.6 .186 –
F3 externally oriented
thinking
20.5 ± 3.8 18.4 ± 5.1 23.2 ± 4.7 21.2 ± 5.3 3.9 .012 CT>HD (p¼ .001)
Table 1. General information of CKD patients groups.
Peritoneal dialysis
(n¼ 19)
(PD)
Hemodialysis
(n¼ 35)
(HD)
Conservative treatment
(n¼ 16)
(CT)
Kidney transplant
(n¼ 9)
(KT)
Total
(n¼ 79)
Gender F/M 4/15 16/19 3/13 1/8 24/55
Age (years) 64.6 ± 10.6 63.3 ± 11.0 71.0 ± 7.9 47.9 ± 11.4 63.4 ± 12.0
Treatment duration (months) 41.0 ± 33.0 82.4 ± 91.3 38.2 ± 89.6 82.3 ± 55.9 63.8 ± 78.6
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calcium values compared to CT (9.8 ± 2.4; p¼ .008), and
KT patients (10.0 ± 0.5; p¼ .008); PD patients (4.9 ± 1.2;
p¼ .009) presented significantly lower serum uric acid
values than HD patients (6.1 ± 1.3); PD patients
(7.9 ± 2.9) presented significantly higher phosphorus
concentration than HD patients (5.1 ± 1.5; p¼ .0001), CT
(3.7 ± 0.73; p¼ .0001) and KT patients (3.9 ± 0.9;
p¼ .0001). Moreover, HD patients (5.1 ± 1.5) presented
significantly higher phosphorus concentration than CT
patients (3.7 ± 0.7; p¼ .012). HD patients (11.1 ± 1.3)
showed significantly lower hemoglobin levels than CT
(12.6 ± 1.4; p¼ .0009) and KT (13.2 ± 1.3; p< .0001)
patients; PD patients (11.9 ± 0.7) presented significantly
lower hemoglobin levels than KT (13.2 ± 1.3; p¼ .014).
Finally, in PD patients, TAS-20 F3 dimension showed
a significant negative correlation with hemoglobin lev-
els (r¼.69; p¼ .001) and a mild positive correlation
with phosphorus concentration (r¼ .45; p¼ .050).
Discussion
Patients treated with PD showed higher levels of anhe-
donia mainly in the sensorial experience dimension and
higher levels of serum phosphorus suggesting a lack of
adherence to the treatment. This finding confirms that
PD patients have greater difficulties to adhere to the
treatment and to the dietetic regimen.13 The lower cap-
acity to feel pleasure in sensorial activities, such as eat-
ing, reflected the greater difficulty to adhere to the
dietetic regimen. A possible explanation of these find-
ings is that in PD patients the pathological condition
invades the home environment causing difficulties in
the perception of pleasure during their daily activity.18,13
Coherently with a previous study,19 the findings of the
present study suggest that despite the peritoneal
treatment allows the patients to take responsibility
about self-control and management of dietetic regimen,
it seems that this greater autonomy could produce a
lower self-management and a lower adherence to medi-
cation regimen. Patients undergoing PD need more
attention by medical staff as their experienced psycho-
logical stress could affect adherence to treatment,
as shown in previous studies in patients
undergoing KT.20,21
HD and PD patients showed significantly lower levels
of hemoglobin than CT and KT patients. Moreover, only
in PD patients, hemoglobin levels were inversely corre-
lated with TAS-20 F3 dimension. This finding confirms
the recent hypothesis that hemoglobin levels could be
affected by the psychological status of dialyzed
patients.22
Patients undergoing peritoneal treatment showed
significantly higher concentration of phosphorus.
Moreover, phosphorus level in PD patients was mildly
correlated with TAS-20 F3 dimension suggesting that a
psychological support could be useful to increase the
adherence in PD patients with a greater difficulty to
elaborate emotions, as shown in a previous study.23
Previous studies investigated the relationship between
serum phosphorus and CKD progression,24–26 suggest-
ing that phosphorus is an independent predictor of
CKD progression and cardiovascular mortality. Short-
term studies have shown that dietary phosphate reduc-
tion effectively decreases FGF-23 levels that seem to be
a direct cause of left ventricular hypertrophy.26,27
Therefore, a significant reduction of phosphorus con-
centration should be recommended in end stage CKD
patients in order to reduce systemic complications of
dialyzed patients and cardiovascular risk. The results of
the present study suggest to plan researches in order to
Table 3. ANOVAs and post hoc comparisons among the different chronic kidney disease treatments (Peritoneal dialysis,
Hemodialysis, Conservative treatment, and Kidney transplant) on the biological markers of adherence.
Peritoneal dialysis
(n¼ 19)
(PD)
Hemodialysis
(n¼ 35)
(HD)
Conservative treatment
(n¼ 16)
(CT)
Kidney transplant
(n¼ 9)
(KT) F(3,75) p Post hoc
Nitrogen 122.8 ± 47.9 141.6 ± 32.0 81.1 ± 40.3 69.8 ± 34.5 14.1 <.0001 PD> CT (p¼ .001)
HD> KT (p¼ .0001)
Potassium 4.5 ± 0.6 5.1 ± 0.7 4.8 ± 0.5 5.1 ± 0.4 4.3 .007 HD> PD (p¼ .028)
KT> PD (p¼ .009)
Calcium 8.9 ± 0.7 8.5 ± 1.4 9.8 ± 2.4 10.0 ± 0.5 3.9 .01 CT>HD (p¼ .008)
KT>HD (p¼ .008)
Uricemia 4.9 ± 1.6 6.1 ± 1.3 6.0 ± 2.3 6.0 ± 1.8 2.5 .065 HD> PD (p¼ .009)
Phosphorus 7.9 ± 2.9 5.1 ± 1.5 3.7 ± 0.7 3.9 ± 0.9 19.0 <.0001 PD>HD (p¼ .0001)
PD> CT (p¼ .0001)
PD> KT (p¼ .0001)
HD> CT (p¼ .012)
Hemoglobin 11.9 ± 0.7 11.1 ± 1.3 12.6 ± 1.4 13.2 ± 1.3 8.2 .0001 CT>HD (p¼ .0009)
KT>HD (p<.0001)
KT> PD (p<.014)
Plasma glucose 95.3 ± 13.8 111.2 ± 39.0 96.3 ± 15.0 94.1 ± 23.9 1.5 .23 –
Blood lipid level 184.1 ± 68.6 187.5 ± 106.0 139.7 ± 65.3 224.3 ± 136.2 1.5 .23 KT> CT (p¼ .047)
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test whether specific psycho-social treatments could
increase self-control and management of dietetic regi-
men in peritoneal patients.28,29
Another important finding was that patients man-
aged with conservative therapy showed greater emo-
tional impairment with a lower attitude to feel and deal
with their emotions compared to patients treated with
HD. The interpretation of this data could be that patients
in the first stages of the CKD could avoid to focus their
attention on internal emotional state. Patients could
implement this defense mechanism in order to keep
themselves away from depressive feelings related to
their chronic condition, as reported in previous stud-
ies.10,30 On the other hand, in patients treated with HD,
the impact of the treatment on their life style could pre-
vent the possibility to avoid the emotional consequen-
ces of their illness status. This result suggests to plan a
psycho-social treatment on patients treated with conser-
vative therapy in order to help them in the management
of the emotional states associated to their condition.
An important limitation of the present study was
that we did not measure the adherence perception of
the patients. It could be interesting to compare it with
the biological marker of patients’ adherence.
In conclusion, the present study showed that peri-
toneal treatment could decrease psychological well
being and adherence to treatment in end stage CKD.
The results suggest to plan psychosocial intervention in
order to increase emotional ability and the adherence
to the therapeutic regimen, reducing cardiovascular risk
since the first stages of CKD.20
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